Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1014 - DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR-TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model


11 Sep 2017


Poster display session


Takeshi Jimbo


Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367


T. Jimbo1, T. Taira1, T. Komatsu1, K. Kumazawa2, N. Maeda1, N. Haginoya1, T. Suzuki3, M. Ota4, Y. Totoki5, C. Wada5, K. Inaki5, T. Isoyama1, M. Uno1

Author affiliations

  • 1 Oncology Function, Daiichi Sankyo Co., LTD, 140-8710 - Tokyo/JP
  • 2 Quality & Safety Management Division, Daiichi Sankyo Co., LTD, Tokyo/JP
  • 3 Biologics Division, Daiichi Sankyo Co., LTD, 140-8710 - Tokyo/JP
  • 4 Research Management Department, Daiichi Sankyo RD Novare Co., LTD, Tokyo/JP
  • 5 Discovery Science And Technology Department, Daiichi Sankyo RD Novare Co., LTD, Tokyo/JP


Abstract 1014


AXL is a receptor tyrosine kinase that plays an important role in signal transduction in normal and malignant cells. Abnormal expression and/or activation of AXL can provide a survival advantage for certain cancer cells, and AXL up-regulation is associated with poor prognosis in several cancers. Recently, it has been reported that up-regulation of AXL expression is a mechanism of EGFR-TKI resistance in EGFR-mutant non-small cell lung cancer.


Kinase activity was measured by mobility shift assay. The inhibition of hGAS6-induced migration was measured in AXL-transfected NIH3T3 (NIH3T3-AXL) cells. The in vivo anti-tumor effects of DS-1205b mono- and combination-therapy with EGFR-TKI were evaluated in NIH3T3-AXL allograft and HCC827 xenograft models. Protein expression was analyzed by Western blot or immunohistochemistry and gene expression was analyzed by RT-PCR or RNA seq.


We found that DS-1205b selectively inhibited AXL kinase activity with IC50 of 1.3 nM, and with NIH3T3-AXL cells, DS-1205b potently inhibited the hGAS6-induced migration in vitro with EC50 of 2.7 nM. DS-1205b monotherapy exerted significant antitumor activity in an NIH3T3-AXL allograft model. In an HCC827 xenograft model, combination treatment with DS-1205b and osimertinib significantly delayed on the onset of tumor resistance compared to osimertinib alone in a manner proportional to DS-1205b does. DS-1205b also showed a similar resistance delay effect with erlotinib combination in the same xenograft model. AXL up-regulation was associated with the development of resistance to erlotinib treatment in another HCC827 xenograft study, and DS-1205b restored the antitumor activity of erlotinib in erlotinib-resistant tumors in a dose-dependent manner.


In an HCC827 xenograft model of EGFR-mutant NSCLC, inhibition of AXL activity by DS-1205b restored sensitivity to erlotinib, and addition of DS-1205b to osimertinib delayed the onset of resistance to osimertinib. These findings support further non-clinical and clinical studies targeting inhibition of AXL in EGFRm NSCLC.

Clinical trial identification

Legal entity responsible for the study

Daiichi Sankyo Co., Ltd.


Daiichi Sankyo Co., Ltd.


T. Jimbo, T. Taira, T. Komatsu, K. Kumazawa, N. Maeda, N. Haginoya, T. Suzuki, M. Ota, Y. Totoki, C. Wada, K. Inaki, T. Isoyama, M. Uno: All authors are employees of Daiichi Sankyo Group which is developing DS-1205c.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.